Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative CT-scan to evaluate cerebral edema secondary to hyperammonemia in ICU: A proof-of-concept study.

Journal of intensive medicine·2026
Same author

Pre-TIPS Liver and Spleen Volumetry Are Not Associated With Liver-Related Outcomes After TIPS Placement for Refractory Ascites.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

JHEP reports : innovation in hepatology·2026
Same author

Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Interobserver agreement in the assessment of active bleeding at endoscopy in patients with cirrhosis and acute variceal bleeding.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same author

Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Acupuncture versus sham non-acupoint acupuncture for irritable bowel syndrome: a systematic review and meta-analysis.

Gastroenterology·2026
Same journal

The Management of Fulminant C. difficile Infection in an Immunocompromised Patient: Balancing Risk and Necessity.

Gastroenterology·2026
Same journal

Rome V Criteria for Anorectal Disorders: The Good and the Useful.

Gastroenterology·2026
Same journal

A Kidney Transplant Recipient with Severe Chronic Diarrhea and Villous Atrophy.

Gastroenterology·2026
Same journal

A Clinical Perspective on Comparative Models of Pancreatic Cyst Surveillance.

Gastroenterology·2026
Same journal

Reply to Jiang et al.

Gastroenterology·2026
See all related articles

Related Experiment Videos

Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced

Didier Lebrec1, Dominique Thabut, Frederic Oberti

  • 1INSERM, Unité 773, Centre de Recherche Biomédicle Bichat-Beaujon CRB3, Paris, France and Service d'Hépatologie, Hôpital Beaujon, Clichy, France. didier.lebrec@inserm.fr

Gastroenterology
|January 28, 2010
PubMed
Summary
This summary is machine-generated.

Pentoxifylline did not reduce mortality in advanced cirrhosis patients but significantly lowered the risk of liver-related complications. This finding is crucial for managing patients with severe liver disease.

Related Experiment Videos

Area of Science:

  • Hepatology
  • Pharmacology
  • Clinical Trials

Background:

  • Advanced cirrhosis poses significant risks, including high mortality and frequent complications.
  • Pentoxifylline, a tumor necrosis factor-alpha inhibitor, has potential therapeutic benefits in liver disease, but its efficacy in advanced cirrhosis was previously unknown.

Purpose of the Study:

  • To evaluate the effects of pentoxifylline on mortality and liver-related complications in patients with advanced cirrhosis (Child-Pugh class C).

Main Methods:

  • A randomized, placebo-controlled, double-blind trial involving 335 patients with Child-Pugh class C cirrhosis.
  • Patients received either pentoxifylline (400 mg, 3 times daily) or a placebo for 6 months.
  • Primary endpoint was mortality at 2 months; secondary endpoints included mortality at 6 months and development of liver-related complications.

Main Results:

  • No significant difference in mortality was observed between the pentoxifylline and placebo groups at 2 months (16.5% vs 18.2%) or 6 months (30.0% vs 31.5%).
  • Patients receiving pentoxifylline showed a significantly higher proportion of survival without complications at 2 months (78.6% vs 63.4%) and 6 months (66.8% vs 49.7%).
  • Pentoxifylline treatment was independently associated with a reduced risk of liver-related complications, while age, MELD score, and early-stage carcinoma were associated with death.

Conclusions:

  • Pentoxifylline does not improve short-term mortality in patients with advanced cirrhosis.
  • Pentoxifylline effectively reduces the incidence of liver-related complications in this patient population.